Advancing Novel Therapeutics for Women’s Reproductive Health

ObsEva is advancing a pipeline of orally administered, clinical-stage innovative compounds to treat women’s reproductive health conditions.

Our Pipeline

Overview

ObsEva is advancing three product candidates through clinical development across a total of four indications.

Product candidate

Preclincal

Phase 1

Phase 2

Phase 3

Next milestones

Commercial rights

Nolasiban

Oral oxytocin
receptor antagonist


Exclusive worldwide

Linzagolix

(OBE2109)
Oral GnRH receptor antagonist

LT follow-up completed 1H:19


Initiated Phase 3
Q2 2019



24W Primary Endpoint
Data Q4 2019-Q1 2020

NDA targeted end of 2020

Exclusive worldwide (ex-Asia)

OBE022

Oral PGF2α receptor antagonist


EU Phase 2a PROLONG
Interim Efficacy Q4 2019


Exclusive worldwide

* Study completed: Week 10 ongoing pregnancy primary endpoint met – Live Birth Rate secondary endpoint met

** Second Phase 3 trial (EU/Canada/Russia): recruitment completed (May2019)

*** Study completed: Primary and secondary endpoints met

Clinical Studies

We are currently conducting six international clinical research studies.

Read more